CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Rasagiline mesylate

Last Updated: September 1, 2006
Result type: Reports
Project Number: SR0073-000
Product Line: Reimbursement Review

Generic Name: Rasagiline mesylate

Brand Name: Azilect

Manufacturer: Teva Neurosciences

Therapeutic Area: Parkinson's disease

Indications: Parkinson's disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 28, 2007

Recommendation Type: Do not list